source
- Updated: GSK reveals three-year blueprint to cut costs and propel R&DJust a little over six months into his tenure as CEO at GSK, Luke Miels is making his mark. The drugmaker on Tuesday outlined plans for a three-year cost-cutting initiative, the launch of at least ...
- Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismAltimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a wee…